01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
retatrutide glp-1 receptor agonist Retatrutide, a GIP, and glucagon agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA RETATRUTIDE: A Medication for Diabetes
Description
Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al
Acadia had previously acquired the candidate through a USD 10 million purchase of Levo Therapeutics
It works through a 4-phase approach designed to optimize your metabolism, reduce inflammation, and promote lasting weight loss results
Additionally, these medications have been shown to protect kidney function
Studies show that when people quit GLP-1 medications after a year, they tend to regain up to two-thirds of the weight they lost
